Cover Page
Cover Page - shares shares in Thousands | 6 Months Ended | |
Mar. 26, 2022 | Apr. 15, 2022 | |
Entity Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 26, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-36743 | |
Entity Registrant Name | Apple Inc. | |
Entity Incorporation, State or Country Code | CA | |
Entity Tax Identification Number | 94-2404110 | |
Entity Address, Address Line One | One Apple Park Way | |
Entity Address, City or Town | Cupertino | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95014 | |
City Area Code | 408 | |
Local Phone Number | 996-1010 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 16,185,181 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0000320193 | |
Current Fiscal Year End Date | --09-24 | |
Common Stock | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | Common Stock, $0.00001 par value per share | |
Trading Symbol | AAPL | |
Security Exchange Name | NASDAQ | |
1.000% Notes due 2022 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 1.000% Notes due 2022 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
1.375% Notes due 2024 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 1.375% Notes due 2024 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
0.000% Notes due 2025 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 0.000% Notes due 2025 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
0.875% Notes due 2025 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 0.875% Notes due 2025 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
1.625% Notes due 2026 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 1.625% Notes due 2026 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
2.000% Notes due 2027 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 2.000% Notes due 2027 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
1.375% Notes due 2029 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 1.375% Notes due 2029 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
3.050% Notes due 2029 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 3.050% Notes due 2029 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
0.500% Notes due 2031 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 0.500% Notes due 2031 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ | |
3.600% Notes due 2042 | ||
Entity Information [Line Items] | ||
Title of 12(b) Security | 3.600% Notes due 2042 | |
No Trading Symbol Flag | true | |
Security Exchange Name | NASDAQ |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Net sales | $ 97,278 | $ 89,584 | $ 221,223 | $ 201,023 |
Cost of sales | 54,719 | 51,505 | 124,421 | 118,616 |
Gross margin | 42,559 | 38,079 | 96,802 | 82,407 |
Operating expenses: | ||||
Research and development | 6,387 | 5,262 | 12,693 | 10,425 |
Selling, general and administrative | 6,193 | 5,314 | 12,642 | 10,945 |
Total operating expenses | 12,580 | 10,576 | 25,335 | 21,370 |
Operating income | 29,979 | 27,503 | 71,467 | 61,037 |
Other income/(expense), net | 160 | 508 | (87) | 553 |
Income before provision for income taxes | 30,139 | 28,011 | 71,380 | 61,590 |
Provision for income taxes | 5,129 | 4,381 | 11,740 | 9,205 |
Net income | $ 25,010 | $ 23,630 | $ 59,640 | $ 52,385 |
Earnings per share: | ||||
Basic (in dollars per share) | $ 1.54 | $ 1.41 | $ 3.65 | $ 3.11 |
Diluted (in dollars per share) | $ 1.52 | $ 1.40 | $ 3.62 | $ 3.08 |
Shares used in computing earnings per share: | ||||
Basic (in shares) | 16,278,802 | 16,753,476 | 16,335,263 | 16,844,298 |
Diluted (in shares) | 16,403,316 | 16,929,157 | 16,461,304 | 17,021,423 |
Products | ||||
Net sales | $ 77,457 | $ 72,683 | $ 181,886 | $ 168,361 |
Cost of sales | 49,290 | 46,447 | 113,599 | 108,577 |
Services | ||||
Net sales | 19,821 | 16,901 | 39,337 | 32,662 |
Cost of sales | $ 5,429 | $ 5,058 | $ 10,822 | $ 10,039 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 25,010 | $ 23,630 | $ 59,640 | $ 52,385 |
Other comprehensive income/(loss): | ||||
Change in foreign currency translation, net of tax | (21) | (78) | (381) | 471 |
Change in unrealized gains/losses on derivative instruments, net of tax: | ||||
Change in fair value of derivative instruments | 334 | 332 | 696 | 28 |
Adjustment for net (gains)/losses realized and included in net income | (301) | 759 | (208) | 576 |
Total change in unrealized gains/losses on derivative instruments | 33 | 1,091 | 488 | 604 |
Change in unrealized gains/losses on marketable debt securities, net of tax: | ||||
Change in fair value of marketable debt securities | (5,633) | (1,403) | (6,809) | (775) |
Adjustment for net (gains)/losses realized and included in net income | 54 | (75) | 45 | (180) |
Total change in unrealized gains/losses on marketable debt securities | (5,579) | (1,478) | (6,764) | (955) |
Total other comprehensive income/(loss) | (5,567) | (465) | (6,657) | 120 |
Total comprehensive income | $ 19,443 | $ 23,165 | $ 52,983 | $ 52,505 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 28,098 | $ 34,940 |
Marketable securities | 23,413 | 27,699 |
Accounts receivable, net | 20,815 | 26,278 |
Inventories | 5,460 | 6,580 |
Vendor non-trade receivables | 24,585 | 25,228 |
Other current assets | 15,809 | 14,111 |
Total current assets | 118,180 | 134,836 |
Non-current assets: | ||
Marketable securities | 141,219 | 127,877 |
Property, plant and equipment, net | 39,304 | 39,440 |
Other non-current assets | 51,959 | 48,849 |
Total non-current assets | 232,482 | 216,166 |
Total assets | 350,662 | 351,002 |
Current liabilities: | ||
Accounts payable | 52,682 | 54,763 |
Other current liabilities | 50,248 | 47,493 |
Deferred revenue | 7,920 | 7,612 |
Commercial paper | 6,999 | 6,000 |
Term debt | 9,659 | 9,613 |
Total current liabilities | 127,508 | 125,481 |
Non-current liabilities: | ||
Term debt | 103,323 | 109,106 |
Other non-current liabilities | 52,432 | 53,325 |
Total non-current liabilities | 155,755 | 162,431 |
Total liabilities | 283,263 | 287,912 |
Commitments and contingencies | ||
Shareholders’ equity: | ||
Common stock and additional paid-in capital, $0.00001 par value: 50,400,000 shares authorized; 16,207,568 and 16,426,786 shares issued and outstanding, respectively | 61,181 | 57,365 |
Retained earnings | 12,712 | 5,562 |
Accumulated other comprehensive income/(loss) | (6,494) | 163 |
Total shareholders’ equity | 67,399 | 63,090 |
Total liabilities and shareholders’ equity | $ 350,662 | $ 351,002 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Mar. 26, 2022 | Sep. 25, 2021 |
Statement of Financial Position [Abstract] | ||
Common stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Common stock, shares authorized (in shares) | 50,400,000,000 | 50,400,000,000 |
Common stock, shares issued (in shares) | 16,207,568,000 | 16,426,786,000 |
Common stock, shares outstanding (in shares) | 16,207,568,000 | 16,426,786,000 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Millions | Total | Common stock and additional paid-in capital | Retained earnings | Accumulated other comprehensive income/(loss) |
Beginning balances at Sep. 26, 2020 | $ 65,339 | $ 50,779 | $ 14,966 | $ (406) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Common stock issued | 561 | |||
Common stock withheld related to net share settlement of equity awards | (1,236) | (2,047) | ||
Share-based compensation | 4,099 | |||
Net income | 52,385 | 52,385 | ||
Dividends and dividend equivalents declared | (7,042) | |||
Common stock repurchased | (43,001) | |||
Other comprehensive income/(loss) | 120 | 120 | ||
Ending balances at Mar. 27, 2021 | $ 69,178 | 54,203 | 15,261 | (286) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | $ 0.41 | |||
Beginning balances at Dec. 26, 2020 | $ 66,224 | 51,744 | 14,301 | 179 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Common stock issued | 561 | |||
Common stock withheld related to net share settlement of equity awards | (135) | (174) | ||
Share-based compensation | 2,033 | |||
Net income | 23,630 | 23,630 | ||
Dividends and dividend equivalents declared | (3,495) | |||
Common stock repurchased | (19,001) | |||
Other comprehensive income/(loss) | (465) | (465) | ||
Ending balances at Mar. 27, 2021 | $ 69,178 | 54,203 | 15,261 | (286) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | $ 0.205 | |||
Beginning balances at Sep. 25, 2021 | $ 63,090 | 57,365 | 5,562 | 163 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Common stock issued | 593 | |||
Common stock withheld related to net share settlement of equity awards | (1,412) | (1,920) | ||
Share-based compensation | 4,635 | |||
Net income | 59,640 | 59,640 | ||
Dividends and dividend equivalents declared | (7,298) | |||
Common stock repurchased | (43,300) | (43,272) | ||
Other comprehensive income/(loss) | (6,657) | (6,657) | ||
Ending balances at Mar. 26, 2022 | $ 67,399 | 61,181 | 12,712 | (6,494) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | $ 0.44 | |||
Beginning balances at Dec. 25, 2021 | $ 71,932 | 58,424 | 14,435 | (927) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Common stock issued | 593 | |||
Common stock withheld related to net share settlement of equity awards | (149) | (190) | ||
Share-based compensation | 2,313 | |||
Net income | 25,010 | 25,010 | ||
Dividends and dividend equivalents declared | (3,633) | |||
Common stock repurchased | (22,910) | |||
Other comprehensive income/(loss) | (5,567) | (5,567) | ||
Ending balances at Mar. 26, 2022 | $ 67,399 | $ 61,181 | $ 12,712 | $ (6,494) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | $ 0.22 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions | 6 Months Ended | |
Mar. 26, 2022 | Mar. 27, 2021 | |
Statement of Cash Flows [Abstract] | ||
Cash, cash equivalents and restricted cash, beginning balances | $ 35,929 | $ 39,789 |
Operating activities: | ||
Net income | 59,640 | 52,385 |
Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 5,434 | 5,463 |
Share-based compensation expense | 4,517 | 4,001 |
Deferred income tax expense/(benefit) | 1,088 | (207) |
Other | (20) | (474) |
Changes in operating assets and liabilities: | ||
Accounts receivable, net | 5,542 | (2,347) |
Inventories | 1,065 | (1,226) |
Vendor non-trade receivables | 643 | 6,792 |
Other current and non-current assets | (3,542) | (4,333) |
Accounts payable | (1,750) | (1,997) |
Deferred revenue | 627 | 1,642 |
Other current and non-current liabilities | 1,888 | 3,045 |
Cash generated by operating activities | 75,132 | 62,744 |
Investing activities: | ||
Purchases of marketable securities | (61,987) | (74,424) |
Proceeds from maturities of marketable securities | 18,000 | 39,605 |
Proceeds from sales of marketable securities | 24,668 | 21,645 |
Payments for acquisition of property, plant and equipment | (5,317) | (5,769) |
Payments made in connection with business acquisitions, net | (167) | (9) |
Other | (568) | 0 |
Cash used in investing activities | (25,371) | (18,952) |
Financing activities: | ||
Payments for taxes related to net share settlement of equity awards | (3,218) | (3,160) |
Payments for dividends and dividend equivalents | (7,327) | (7,060) |
Repurchases of common stock | (43,109) | (43,323) |
Proceeds from issuance of term debt, net | 0 | 13,923 |
Repayments of term debt | (3,750) | (4,500) |
Proceeds from commercial paper, net | 999 | 22 |
Other | (105) | 523 |
Cash used in financing activities | (56,510) | (43,575) |
Increase/(Decrease) in cash, cash equivalents and restricted cash | (6,749) | 217 |
Cash, cash equivalents and restricted cash, ending balances | 29,180 | 40,006 |
Supplemental cash flow disclosure: | ||
Cash paid for income taxes, net | 9,301 | 10,276 |
Cash paid for interest | $ 1,406 | $ 1,327 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Mar. 26, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation and Preparation The condensed consolidated financial statements include the accounts of Apple Inc. and its wholly owned subsidiaries (collectively “Apple” or the “Company”). Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. Certain prior period amounts in the condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended September 25, 2021. The Company’s fiscal year is the 52- or 53-week period that ends on the last Saturday of September. An additional week is included in the first fiscal quarter every five or six years to realign the Company’s fiscal quarters with calendar quarters. The Company’s fiscal years 2022 and 2021 span 52 weeks each. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years. Earnings Per Share The following table shows the computation of basic and diluted earnings per share for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (net income in millions and shares in thousands): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Numerator: Net income $ 25,010 $ 23,630 $ 59,640 $ 52,385 Denominator: Weighted-average basic shares outstanding 16,278,802 16,753,476 16,335,263 16,844,298 Effect of dilutive securities 124,514 175,681 126,041 177,125 Weighted-average diluted shares 16,403,316 16,929,157 16,461,304 17,021,423 Basic earnings per share $ 1.54 $ 1.41 $ 3.65 $ 3.11 Diluted earnings per share $ 1.52 $ 1.40 $ 3.62 $ 3.08 |
Revenue
Revenue | 6 Months Ended |
Mar. 26, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue Net sales disaggregated by significant products and services for the three- and six-month periods ended March 26, 2022 and March 27, 2021 were as follows (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, iPhone ® (1) $ 50,570 $ 47,938 $ 122,198 $ 113,535 Mac ® (1) 10,435 9,102 21,287 17,777 iPad ® (1) 7,646 7,807 14,894 16,242 Wearables, Home and Accessories (1)(2) 8,806 7,836 23,507 20,807 Services (3) 19,821 16,901 39,337 32,662 Total net sales (4) $ 97,278 $ 89,584 $ 221,223 $ 201,023 (1) Products net sales include amortization of the deferred value of unspecified software upgrade rights, which are bundled in the sales price of the respective product. (2) Wearables, Home and Accessories net sales include sales of AirPods ® , Apple TV ® , Apple Watch ® , Beats ® products, HomePod mini ® , iPod touch ® and accessories. (3) Services net sales include sales from the Company’s advertising, AppleCare ® , cloud, digital content, payment and other services. Services net sales also include amortization of the deferred value of services bundled in the sales price of certain products. (4) Includes $3.0 billion of revenue recognized in the three months ended March 26, 2022 that was included in deferred revenue as of December 25, 2021, $2.7 billion of revenue recognized in the three months ended March 27, 2021 that was included in deferred revenue as of December 26, 2020, $4.8 billion of revenue recognized in the six months ended March 26, 2022 that was included in deferred revenue as of September 25, 2021, and $4.1 billion of revenue recognized in the six months ended March 27, 2021 that was included in deferred revenue as of September 26, 2020. The Company’s proportion of net sales by disaggregated revenue source was generally consistent for each reportable segment in Note 9, “Segment Information and Geographic Data” for the three- and six-month periods ended March 26, 2022 and March 27, 2021, except in Greater China, where iPhone revenue represented a moderately higher proportion of net sales. As of March 26, 2022 and September 25, 2021, the Company had total deferred revenue of $12.5 billion and $11.9 billion, respectively. As of March 26, 2022, the Company expects 63% of total deferred revenue to be realized in less than a year, 27% within one-to-two years, 8% within two-to-three years and 2% in greater than three years. |
Financial Instruments
Financial Instruments | 6 Months Ended |
Mar. 26, 2022 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | Financial Instruments Cash, Cash Equivalents and Marketable Securities The following tables show the Company’s cash, cash equivalents and marketable securities by significant investment category as of March 26, 2022 and September 25, 2021 (in millions): March 26, 2022 Adjusted Unrealized Unrealized Fair Cash and Current Non-Current Marketable Cash $ 14,298 $ — $ — $ 14,298 $ 14,298 $ — $ — Level 1 (1) : Money market funds 7,653 — — 7,653 7,653 — — Mutual funds 230 7 (9) 228 — 228 — Subtotal 7,883 7 (9) 7,881 7,653 228 — Level 2 (2) : Equity securities 1,527 — (1,132) 395 — 395 — U.S. Treasury securities 28,711 2 (1,037) 27,676 2,306 3,554 21,816 U.S. agency securities 6,561 — (407) 6,154 251 683 5,220 Non-U.S. government securities 18,868 44 (551) 18,361 25 4,526 13,810 Certificates of deposit and time deposits 2,872 — — 2,872 2,221 601 50 Commercial paper 2,913 — — 2,913 1,310 1,603 — Corporate debt securities 93,057 94 (4,266) 88,885 34 11,309 77,542 Municipal securities 990 1 (22) 969 — 162 807 Mortgage- and asset-backed securities 23,613 3 (1,290) 22,326 — 352 21,974 Subtotal 179,112 144 (8,705) 170,551 6,147 23,185 141,219 Total (3) $ 201,293 $ 151 $ (8,714) $ 192,730 $ 28,098 $ 23,413 $ 141,219 September 25, 2021 Adjusted Unrealized Unrealized Fair Cash and Current Non-Current Cash $ 17,305 $ — $ — $ 17,305 $ 17,305 $ — $ — Level 1 (1) : Money market funds 9,608 — — 9,608 9,608 — — Mutual funds 175 11 (1) 185 — 185 — Subtotal 9,783 11 (1) 9,793 9,608 185 — Level 2 (2) : Equity securities 1,527 — (564) 963 — 963 — U.S. Treasury securities 22,878 102 (77) 22,903 3,596 6,625 12,682 U.S. agency securities 8,949 2 (64) 8,887 1,775 1,930 5,182 Non-U.S. government securities 20,201 211 (101) 20,311 390 3,091 16,830 Certificates of deposit and time deposits 1,300 — — 1,300 490 810 — Commercial paper 2,639 — — 2,639 1,776 863 — Corporate debt securities 83,883 1,242 (267) 84,858 — 12,327 72,531 Municipal securities 967 14 — 981 — 130 851 Mortgage- and asset-backed securities 20,529 171 (124) 20,576 — 775 19,801 Subtotal 162,873 1,742 (1,197) 163,418 8,027 27,514 127,877 Total (3) $ 189,961 $ 1,753 $ (1,198) $ 190,516 $ 34,940 $ 27,699 $ 127,877 (1) Level 1 fair value estimates are based on quoted prices in active markets for identical assets or liabilities. (2) Level 2 fair value estimates are based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. (3) As of March 26, 2022 and September 25, 2021, total marketable securities included $15.4 billion and $17.9 billion, respectively, that were restricted from general use, related to the European Commission decision finding that Ireland granted state aid to the Company, and other agreements. The following table shows the fair value of the Company’s non-current marketable debt securities, by contractual maturity, as of March 26, 2022 (in millions): Due after 1 year through 5 years $ 97,603 Due after 5 years through 10 years 22,899 Due after 10 years 20,717 Total fair value $ 141,219 Derivative Instruments and Hedging The Company may use derivative instruments to partially offset its business exposure to foreign exchange and interest rate risk. However, the Company may choose not to hedge certain exposures for a variety of reasons, including accounting considerations or the prohibitive economic cost of hedging particular exposures. There can be no assurance the hedges will offset more than a portion of the financial impact resulting from movements in foreign exchange or interest rates. Foreign Exchange Risk To protect gross margins from fluctuations in foreign currency exchange rates, the Company may enter into forward contracts, option contracts or other instruments, and may designate these instruments as cash flow hedges. The Company generally hedges portions of its forecasted foreign currency exposure associated with revenue and inventory purchases, typically for up to 12 months. To protect the Company’s foreign currency–denominated term debt or marketable securities from fluctuations in foreign currency exchange rates, the Company may enter into forward contracts, cross-currency swaps or other instruments. The Company designates these instruments as either cash flow or fair value hedges. As of March 26, 2022, the Company’s hedged term debt– and marketable securities–related foreign currency transactions are expected to be recognized within 20 years. The Company may also enter into derivative instruments that are not designated as accounting hedges to protect gross margins from certain fluctuations in foreign currency exchange rates, as well as to offset a portion of the foreign currency exchange gains and losses generated by the remeasurement of certain assets and liabilities denominated in non-functional currencies. Interest Rate Risk To protect the Company’s term debt or marketable securities from fluctuations in interest rates, the Company may enter into interest rate swaps, options or other instruments. The Company designates these instruments as either cash flow or fair value hedges. The notional amounts of the Company’s outstanding derivative instruments as of March 26, 2022 and September 25, 2021 were as follows (in millions): March 26, September 25, Derivative instruments designated as accounting hedges: Foreign exchange contracts $ 65,140 $ 76,475 Interest rate contracts $ 20,775 $ 16,875 Derivative instruments not designated as accounting hedges: Foreign exchange contracts $ 110,758 $ 126,918 The gross fair values of the Company’s derivative assets and liabilities were not material as of March 26, 2022 and September 25, 2021. The gains and losses recognized in other comprehensive income/(loss) and amounts reclassified from accumulated other comprehensive income/(loss) to net income for the Company’s derivative instruments designated as cash flow hedges were not material in the three- and six-month periods ended March 26, 2022 and March 27, 2021. The carrying amounts of the Company’s hedged items in fair value hedges as of March 26, 2022 and September 25, 2021 were as follows (in millions): March 26, September 25, Hedged assets/(liabilities): Current and non-current marketable securities $ 14,943 $ 15,954 Current and non-current term debt $ (19,766) $ (17,857) The gains and losses on the Company’s derivative instruments designated as fair value hedges and the related hedged item adjustments were not material in the three- and six-month periods ended March 26, 2022 and March 27, 2021. Accounts Receivable Trade Receivables The Company has considerable trade receivables outstanding with its third-party cellular network carriers, wholesalers, retailers, resellers, small and mid-sized businesses and education, enterprise and government customers. The Company generally does not require collateral from its customers; however, the Company will require collateral or third-party credit support in certain instances to limit credit risk. In addition, when possible, the Company attempts to limit credit risk on trade receivables with credit insurance for certain customers or by requiring third-party financing, loans or leases to support credit exposure. These credit-financing arrangements are directly between the third-party financing company and the end customer. As such, the Company generally does not assume any recourse or credit risk sharing related to any of these arrangements. The Company’s cellular network carriers accounted for 36% and 42% of total trade receivables as of March 26, 2022 and September 25, 2021, respectively. Vendor Non-Trade Receivables The Company has non-trade receivables from certain of its manufacturing vendors resulting from the sale of components to these vendors who manufacture subassemblies or assemble final products for the Company. The Company purchases these components directly from suppliers. As of March 26, 2022, the Company had two vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 52% and 12%. As of September 25, 2021, the Company had three vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 52%, 11% and 11%. |
Condensed Consolidated Financia
Condensed Consolidated Financial Statement Details | 6 Months Ended |
Mar. 26, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Condensed Consolidated Financial Statement Details | Condensed Consolidated Financial Statement Details The following tables show the Company’s condensed consolidated financial statement details as of March 26, 2022 and September 25, 2021 (in millions): Property, Plant and Equipment, Net March 26, September 25, Gross property, plant and equipment $ 109,324 $ 109,723 Accumulated depreciation and amortization (70,020) (70,283) Total property, plant and equipment, net $ 39,304 $ 39,440 Other Non-Current Liabilities March 26, September 25, Long-term taxes payable $ 20,711 $ 24,689 Other non-current liabilities 31,721 28,636 Total other non-current liabilities $ 52,432 $ 53,325 Other Income/(Expense), Net The following table shows the detail of other income/(expense), net for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Interest and dividend income $ 700 $ 718 $ 1,350 $ 1,465 Interest expense (691) (670) (1,385) (1,308) Other income/(expense), net 151 460 (52) 396 Total other income/(expense), net $ 160 $ 508 $ (87) $ 553 |
Debt
Debt | 6 Months Ended |
Mar. 26, 2022 | |
Debt Disclosure [Abstract] | |
Debt | Debt Commercial Paper The Company issues unsecured short-term promissory notes (“Commercial Paper”) pursuant to a commercial paper program. The Company uses net proceeds from the commercial paper program for general corporate purposes, including dividends and share repurchases. As of March 26, 2022 and September 25, 2021, the Company had $7.0 billion and $6.0 billion of Commercial Paper outstanding, respectively. The following table provides a summary of cash flows associated with the issuance and maturities of Commercial Paper for the six months ended March 26, 2022 and March 27, 2021 (in millions): Six Months Ended March 26, March 27, Maturities 90 days or less: Proceeds from commercial paper, net $ 4,952 $ 2,008 Maturities greater than 90 days: Proceeds from commercial paper 1,191 1,368 Repayments of commercial paper (5,144) (3,354) Repayments of commercial paper, net (3,953) (1,986) Total proceeds from commercial paper, net $ 999 $ 22 Term Debt As of March 26, 2022 and September 25, 2021, the Company had outstanding floating- and fixed-rate notes with varying maturities for an aggregate carrying amount of $113.0 billion and $118.7 billion, respectively (collectively the “Notes”). As of March 26, 2022 and September 25, 2021, the fair value of the Company’s Notes, based on Level 2 inputs, was $110.5 billion and $125.3 billion, respectively. |
Shareholders' Equity
Shareholders' Equity | 6 Months Ended |
Mar. 26, 2022 | |
Equity [Abstract] | |
Shareholders' Equity | Shareholders’ Equity Share Repurchase Program During the six months ended March 26, 2022, the Company repurchased 266 million shares of its common stock for $43.3 billion under a share repurchase program authorized by the Board of Directors (the “Program”), including 35 million shares delivered under accelerated share repurchase agreements totaling $6.0 billion that were entered into in November 2021. The Program does not obligate the Company to acquire a minimum amount of shares. Under the Program, shares may be repurchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Benefit Plans
Benefit Plans | 6 Months Ended |
Mar. 26, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Benefit Plans | Benefit Plans Restricted Stock Units A summary of the Company’s restricted stock unit (“RSU”) activity and related information for the six months ended March 26, 2022 is as follows: Number of RSUs (in thousands) Weighted-Average Aggregate Fair Value (in millions) Balance as of September 25, 2021 240,427 $ 75.16 RSUs granted 76,920 $ 149.72 RSUs vested (62,476) $ 62.86 RSUs canceled (8,407) $ 95.86 Balance as of March 26, 2022 246,464 $ 100.84 $ 43,062 The fair value as of the respective vesting dates of RSUs was $1.0 billion and $9.5 billion for the three- and six-month periods ended March 26, 2022, respectively, and was $867 million and $9.4 billion for the three- and six-month periods ended March 27, 2021, respectively. Share-Based Compensation The following table shows share-based compensation expense and the related income tax benefit included in the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Share-based compensation expense $ 2,252 $ 1,981 $ 4,517 $ 4,001 Income tax benefit related to share-based compensation expense $ (649) $ (575) $ (2,185) $ (2,199) As of March 26, 2022, the total unrecognized compensation cost related to outstanding RSUs and stock options was $19.3 billion, which the Company expects to recognize over a weighted-average period of 2.8 years. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Mar. 26, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Accrued Warranty The following table shows changes in the Company’s accrued warranties and related costs for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Beginning accrued warranty and related costs $ 3,530 $ 4,124 $ 3,364 $ 3,354 Cost of warranty claims (581) (649) (1,253) (1,372) Accruals for product warranty 257 309 1,095 1,802 Ending accrued warranty and related costs $ 3,206 $ 3,784 $ 3,206 $ 3,784 Contingencies The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and that have not been fully resolved. The outcome of litigation is inherently uncertain. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss, or a material loss greater than a recorded accrual, concerning loss contingencies for asserted legal and other claims. |
Segment Information and Geograp
Segment Information and Geographic Data | 6 Months Ended |
Mar. 26, 2022 | |
Segment Reporting [Abstract] | |
Segment Information and Geographic Data | Segment Information and Geographic Data The following table shows information by reportable segment for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Americas: Net sales $ 40,882 $ 34,306 $ 92,378 $ 80,616 Operating income $ 15,279 $ 12,050 $ 34,864 $ 27,835 Europe: Net sales $ 23,287 $ 22,264 $ 53,036 $ 49,570 Operating income $ 8,505 $ 8,265 $ 20,050 $ 17,854 Greater China: Net sales $ 18,343 $ 17,728 $ 44,126 $ 39,041 Operating income $ 8,112 $ 7,758 $ 19,295 $ 16,288 Japan: Net sales $ 7,724 $ 7,742 $ 14,831 $ 16,027 Operating income $ 3,496 $ 3,428 $ 6,845 $ 6,931 Rest of Asia Pacific: Net sales $ 7,042 $ 7,544 $ 16,852 $ 15,769 Operating income $ 2,823 $ 2,736 $ 6,818 $ 5,689 A reconciliation of the Company’s segment operating income to the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 26, 2022 and March 27, 2021 is as follows (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Segment operating income $ 38,215 $ 34,237 $ 87,872 $ 74,597 Research and development expense (6,387) (5,262) (12,693) (10,425) Other corporate expenses, net (1,849) (1,472) (3,712) (3,135) Total operating income $ 29,979 $ 27,503 $ 71,467 $ 61,037 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Mar. 26, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Preparation | Basis of Presentation and Preparation The condensed consolidated financial statements include the accounts of Apple Inc. and its wholly owned subsidiaries (collectively “Apple” or the “Company”). Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. Certain prior period amounts in the condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended September 25, 2021. |
Fiscal Period | The Company’s fiscal year is the 52- or 53-week period that ends on the last Saturday of September. An additional week is included in the first fiscal quarter every five or six years to realign the Company’s fiscal quarters with calendar quarters. The Company’s fiscal years 2022 and 2021 span 52 weeks each. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years. |
Fair Value Measurements | Level 1 fair value estimates are based on quoted prices in active markets for identical assets or liabilities.Level 2 fair value estimates are based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Accounting Policies [Abstract] | |
Computation of Basic and Diluted Earnings Per Share | The following table shows the computation of basic and diluted earnings per share for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (net income in millions and shares in thousands): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Numerator: Net income $ 25,010 $ 23,630 $ 59,640 $ 52,385 Denominator: Weighted-average basic shares outstanding 16,278,802 16,753,476 16,335,263 16,844,298 Effect of dilutive securities 124,514 175,681 126,041 177,125 Weighted-average diluted shares 16,403,316 16,929,157 16,461,304 17,021,423 Basic earnings per share $ 1.54 $ 1.41 $ 3.65 $ 3.11 Diluted earnings per share $ 1.52 $ 1.40 $ 3.62 $ 3.08 |
Revenue (Tables)
Revenue (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Net Sales Disaggregated by Significant Products and Services | Net sales disaggregated by significant products and services for the three- and six-month periods ended March 26, 2022 and March 27, 2021 were as follows (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, iPhone ® (1) $ 50,570 $ 47,938 $ 122,198 $ 113,535 Mac ® (1) 10,435 9,102 21,287 17,777 iPad ® (1) 7,646 7,807 14,894 16,242 Wearables, Home and Accessories (1)(2) 8,806 7,836 23,507 20,807 Services (3) 19,821 16,901 39,337 32,662 Total net sales (4) $ 97,278 $ 89,584 $ 221,223 $ 201,023 (1) Products net sales include amortization of the deferred value of unspecified software upgrade rights, which are bundled in the sales price of the respective product. (2) Wearables, Home and Accessories net sales include sales of AirPods ® , Apple TV ® , Apple Watch ® , Beats ® products, HomePod mini ® , iPod touch ® and accessories. (3) Services net sales include sales from the Company’s advertising, AppleCare ® , cloud, digital content, payment and other services. Services net sales also include amortization of the deferred value of services bundled in the sales price of certain products. (4) Includes $3.0 billion of revenue recognized in the three months ended March 26, 2022 that was included in deferred revenue as of December 25, 2021, $2.7 billion of revenue recognized in the three months ended March 27, 2021 that was included in deferred revenue as of December 26, 2020, $4.8 billion of revenue recognized in the six months ended March 26, 2022 that was included in deferred revenue as of September 25, 2021, and $4.1 billion of revenue recognized in the six months ended March 27, 2021 that was included in deferred revenue as of September 26, 2020. |
Financial Instruments (Tables)
Financial Instruments (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Investments, All Other Investments [Abstract] | |
Cash, Cash Equivalents and Marketable Securities by Significant Investment Category | The following tables show the Company’s cash, cash equivalents and marketable securities by significant investment category as of March 26, 2022 and September 25, 2021 (in millions): March 26, 2022 Adjusted Unrealized Unrealized Fair Cash and Current Non-Current Marketable Cash $ 14,298 $ — $ — $ 14,298 $ 14,298 $ — $ — Level 1 (1) : Money market funds 7,653 — — 7,653 7,653 — — Mutual funds 230 7 (9) 228 — 228 — Subtotal 7,883 7 (9) 7,881 7,653 228 — Level 2 (2) : Equity securities 1,527 — (1,132) 395 — 395 — U.S. Treasury securities 28,711 2 (1,037) 27,676 2,306 3,554 21,816 U.S. agency securities 6,561 — (407) 6,154 251 683 5,220 Non-U.S. government securities 18,868 44 (551) 18,361 25 4,526 13,810 Certificates of deposit and time deposits 2,872 — — 2,872 2,221 601 50 Commercial paper 2,913 — — 2,913 1,310 1,603 — Corporate debt securities 93,057 94 (4,266) 88,885 34 11,309 77,542 Municipal securities 990 1 (22) 969 — 162 807 Mortgage- and asset-backed securities 23,613 3 (1,290) 22,326 — 352 21,974 Subtotal 179,112 144 (8,705) 170,551 6,147 23,185 141,219 Total (3) $ 201,293 $ 151 $ (8,714) $ 192,730 $ 28,098 $ 23,413 $ 141,219 September 25, 2021 Adjusted Unrealized Unrealized Fair Cash and Current Non-Current Cash $ 17,305 $ — $ — $ 17,305 $ 17,305 $ — $ — Level 1 (1) : Money market funds 9,608 — — 9,608 9,608 — — Mutual funds 175 11 (1) 185 — 185 — Subtotal 9,783 11 (1) 9,793 9,608 185 — Level 2 (2) : Equity securities 1,527 — (564) 963 — 963 — U.S. Treasury securities 22,878 102 (77) 22,903 3,596 6,625 12,682 U.S. agency securities 8,949 2 (64) 8,887 1,775 1,930 5,182 Non-U.S. government securities 20,201 211 (101) 20,311 390 3,091 16,830 Certificates of deposit and time deposits 1,300 — — 1,300 490 810 — Commercial paper 2,639 — — 2,639 1,776 863 — Corporate debt securities 83,883 1,242 (267) 84,858 — 12,327 72,531 Municipal securities 967 14 — 981 — 130 851 Mortgage- and asset-backed securities 20,529 171 (124) 20,576 — 775 19,801 Subtotal 162,873 1,742 (1,197) 163,418 8,027 27,514 127,877 Total (3) $ 189,961 $ 1,753 $ (1,198) $ 190,516 $ 34,940 $ 27,699 $ 127,877 (1) Level 1 fair value estimates are based on quoted prices in active markets for identical assets or liabilities. (2) Level 2 fair value estimates are based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. (3) As of March 26, 2022 and September 25, 2021, total marketable securities included $15.4 billion and $17.9 billion, respectively, that were restricted from general use, related to the European Commission decision finding that Ireland granted state aid to the Company, and other agreements. |
Non-Current Marketable Debt Securities by Contractual Maturity | The following table shows the fair value of the Company’s non-current marketable debt securities, by contractual maturity, as of March 26, 2022 (in millions): Due after 1 year through 5 years $ 97,603 Due after 5 years through 10 years 22,899 Due after 10 years 20,717 Total fair value $ 141,219 |
Notional Amounts of Outstanding Derivative Instruments | The notional amounts of the Company’s outstanding derivative instruments as of March 26, 2022 and September 25, 2021 were as follows (in millions): March 26, September 25, Derivative instruments designated as accounting hedges: Foreign exchange contracts $ 65,140 $ 76,475 Interest rate contracts $ 20,775 $ 16,875 Derivative instruments not designated as accounting hedges: Foreign exchange contracts $ 110,758 $ 126,918 |
Carrying Amounts of Hedged Items in Fair Value Hedges | The carrying amounts of the Company’s hedged items in fair value hedges as of March 26, 2022 and September 25, 2021 were as follows (in millions): March 26, September 25, Hedged assets/(liabilities): Current and non-current marketable securities $ 14,943 $ 15,954 Current and non-current term debt $ (19,766) $ (17,857) |
Condensed Consolidated Financ_2
Condensed Consolidated Financial Statement Details (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Property, Plant and Equipment, Net | Property, Plant and Equipment, Net March 26, September 25, Gross property, plant and equipment $ 109,324 $ 109,723 Accumulated depreciation and amortization (70,020) (70,283) Total property, plant and equipment, net $ 39,304 $ 39,440 |
Other Non-Current Liabilities | Other Non-Current Liabilities March 26, September 25, Long-term taxes payable $ 20,711 $ 24,689 Other non-current liabilities 31,721 28,636 Total other non-current liabilities $ 52,432 $ 53,325 |
Other Income/(Expense), Net | Other Income/(Expense), Net The following table shows the detail of other income/(expense), net for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Interest and dividend income $ 700 $ 718 $ 1,350 $ 1,465 Interest expense (691) (670) (1,385) (1,308) Other income/(expense), net 151 460 (52) 396 Total other income/(expense), net $ 160 $ 508 $ (87) $ 553 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Debt Disclosure [Abstract] | |
Summary of Cash Flows Associated with Issuance and Maturities of Commercial Paper | The following table provides a summary of cash flows associated with the issuance and maturities of Commercial Paper for the six months ended March 26, 2022 and March 27, 2021 (in millions): Six Months Ended March 26, March 27, Maturities 90 days or less: Proceeds from commercial paper, net $ 4,952 $ 2,008 Maturities greater than 90 days: Proceeds from commercial paper 1,191 1,368 Repayments of commercial paper (5,144) (3,354) Repayments of commercial paper, net (3,953) (1,986) Total proceeds from commercial paper, net $ 999 $ 22 |
Benefit Plans (Tables)
Benefit Plans (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Restricted Stock Unit Activity | A summary of the Company’s restricted stock unit (“RSU”) activity and related information for the six months ended March 26, 2022 is as follows: Number of RSUs (in thousands) Weighted-Average Aggregate Fair Value (in millions) Balance as of September 25, 2021 240,427 $ 75.16 RSUs granted 76,920 $ 149.72 RSUs vested (62,476) $ 62.86 RSUs canceled (8,407) $ 95.86 Balance as of March 26, 2022 246,464 $ 100.84 $ 43,062 |
Summary of Share-Based Compensation Expense and the Related Income Tax Benefit | The following table shows share-based compensation expense and the related income tax benefit included in the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Share-based compensation expense $ 2,252 $ 1,981 $ 4,517 $ 4,001 Income tax benefit related to share-based compensation expense $ (649) $ (575) $ (2,185) $ (2,199) |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Changes in Accrued Warranties and Related Costs | The following table shows changes in the Company’s accrued warranties and related costs for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Beginning accrued warranty and related costs $ 3,530 $ 4,124 $ 3,364 $ 3,354 Cost of warranty claims (581) (649) (1,253) (1,372) Accruals for product warranty 257 309 1,095 1,802 Ending accrued warranty and related costs $ 3,206 $ 3,784 $ 3,206 $ 3,784 |
Segment Information and Geogr_2
Segment Information and Geographic Data (Tables) | 6 Months Ended |
Mar. 26, 2022 | |
Segment Reporting [Abstract] | |
Information by Reportable Segment | The following table shows information by reportable segment for the three- and six-month periods ended March 26, 2022 and March 27, 2021 (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Americas: Net sales $ 40,882 $ 34,306 $ 92,378 $ 80,616 Operating income $ 15,279 $ 12,050 $ 34,864 $ 27,835 Europe: Net sales $ 23,287 $ 22,264 $ 53,036 $ 49,570 Operating income $ 8,505 $ 8,265 $ 20,050 $ 17,854 Greater China: Net sales $ 18,343 $ 17,728 $ 44,126 $ 39,041 Operating income $ 8,112 $ 7,758 $ 19,295 $ 16,288 Japan: Net sales $ 7,724 $ 7,742 $ 14,831 $ 16,027 Operating income $ 3,496 $ 3,428 $ 6,845 $ 6,931 Rest of Asia Pacific: Net sales $ 7,042 $ 7,544 $ 16,852 $ 15,769 Operating income $ 2,823 $ 2,736 $ 6,818 $ 5,689 |
Reconciliation of Segment Operating Income to the Condensed Consolidated Statements of Operations | A reconciliation of the Company’s segment operating income to the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 26, 2022 and March 27, 2021 is as follows (in millions): Three Months Ended Six Months Ended March 26, March 27, March 26, March 27, Segment operating income $ 38,215 $ 34,237 $ 87,872 $ 74,597 Research and development expense (6,387) (5,262) (12,693) (10,425) Other corporate expenses, net (1,849) (1,472) (3,712) (3,135) Total operating income $ 29,979 $ 27,503 $ 71,467 $ 61,037 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Numerator: | ||||
Net income | $ 25,010 | $ 23,630 | $ 59,640 | $ 52,385 |
Denominator: | ||||
Weighted-average basic shares outstanding (in shares) | 16,278,802 | 16,753,476 | 16,335,263 | 16,844,298 |
Effect of dilutive securities (in shares) | 124,514 | 175,681 | 126,041 | 177,125 |
Weighted-average diluted shares (in shares) | 16,403,316 | 16,929,157 | 16,461,304 | 17,021,423 |
Basic earnings per share (in dollars per share) | $ 1.54 | $ 1.41 | $ 3.65 | $ 3.11 |
Diluted earnings per share (in dollars per share) | $ 1.52 | $ 1.40 | $ 3.62 | $ 3.08 |
Revenue - Net Sales Disaggregat
Revenue - Net Sales Disaggregated by Significant Products and Services (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 97,278 | $ 89,584 | $ 221,223 | $ 201,023 |
Revenue recognized that was included in deferred revenue at the beginning of the period | 3,000 | 2,700 | 4,800 | 4,100 |
iPhone | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 50,570 | 47,938 | 122,198 | 113,535 |
Mac | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 10,435 | 9,102 | 21,287 | 17,777 |
iPad | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 7,646 | 7,807 | 14,894 | 16,242 |
Wearables, Home and Accessories | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 8,806 | 7,836 | 23,507 | 20,807 |
Services | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 19,821 | $ 16,901 | $ 39,337 | $ 32,662 |
Revenue - Additional Informatio
Revenue - Additional Information (Details) - USD ($) $ in Billions | Mar. 26, 2022 | Sep. 25, 2021 |
Revenue from Contract with Customer [Abstract] | ||
Total deferred revenue | $ 12.5 | $ 11.9 |
Revenue - Deferred Revenue, Exp
Revenue - Deferred Revenue, Expected Timing of Realization (Details) | Mar. 26, 2022 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-03-27 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of realization, percentage | 63.00% |
Deferred revenue, expected timing of realization, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-02 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of realization, percentage | 27.00% |
Deferred revenue, expected timing of realization, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-31 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of realization, percentage | 8.00% |
Deferred revenue, expected timing of realization, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-30 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of realization, percentage | 2.00% |
Deferred revenue, expected timing of realization, period |
Financial Instruments - Cash, C
Financial Instruments - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Debt Securities, Available-for-sale [Line Items] | ||
Cash, Cash Equivalents and Marketable Securities, Adjusted Cost | $ 201,293 | $ 189,961 |
Cash Equivalents and Marketable Securities, Unrealized Gains | 151 | 1,753 |
Cash Equivalents and Marketable Securities, Unrealized Losses | (8,714) | (1,198) |
Cash, Cash Equivalents and Marketable Securities, Fair Value | 192,730 | 190,516 |
Cash and Cash Equivalents | 28,098 | 34,940 |
Current Marketable Securities | 23,413 | 27,699 |
Non-Current Marketable Securities | 141,219 | 127,877 |
Total marketable securities that were restricted from general use | 15,400 | 17,900 |
Level 1 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Equity, Adjusted Cost | 7,883 | 9,783 |
Marketable Securities, Equity, Unrealized Gains | 7 | 11 |
Marketable Securities, Equity, Unrealized Losses | (9) | (1) |
Marketable Securities, Equity, Fair Value | 7,881 | 9,793 |
Cash and Cash Equivalents | 7,653 | 9,608 |
Current Marketable Securities | 228 | 185 |
Non-Current Marketable Securities | 0 | 0 |
Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 179,112 | 162,873 |
Marketable Securities, Debt, Unrealized Gains | 144 | 1,742 |
Marketable Securities, Debt, Unrealized Losses | (8,705) | (1,197) |
Marketable Securities, Debt, Fair Value | 170,551 | 163,418 |
Cash and Cash Equivalents | 6,147 | 8,027 |
Current Marketable Securities | 23,185 | 27,514 |
Non-Current Marketable Securities | 141,219 | 127,877 |
Cash | ||
Debt Securities, Available-for-sale [Line Items] | ||
Cash | 14,298 | 17,305 |
Cash and Cash Equivalents | 14,298 | 17,305 |
Current Marketable Securities | 0 | 0 |
Non-Current Marketable Securities | 0 | 0 |
Money market funds | Level 1 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Equity, Adjusted Cost | 7,653 | 9,608 |
Marketable Securities, Equity, Unrealized Gains | 0 | 0 |
Marketable Securities, Equity, Unrealized Losses | 0 | 0 |
Marketable Securities, Equity, Fair Value | 7,653 | 9,608 |
Cash and Cash Equivalents | 7,653 | 9,608 |
Current Marketable Securities | 0 | 0 |
Non-Current Marketable Securities | 0 | 0 |
Mutual funds | Level 1 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Equity, Adjusted Cost | 230 | 175 |
Marketable Securities, Equity, Unrealized Gains | 7 | 11 |
Marketable Securities, Equity, Unrealized Losses | (9) | (1) |
Marketable Securities, Equity, Fair Value | 228 | 185 |
Cash and Cash Equivalents | 0 | 0 |
Current Marketable Securities | 228 | 185 |
Non-Current Marketable Securities | 0 | 0 |
Equity securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Equity, Adjusted Cost | 1,527 | 1,527 |
Marketable Securities, Equity, Unrealized Gains | 0 | 0 |
Marketable Securities, Equity, Unrealized Losses | (1,132) | (564) |
Marketable Securities, Equity, Fair Value | 395 | 963 |
Cash and Cash Equivalents | 0 | 0 |
Current Marketable Securities | 395 | 963 |
Non-Current Marketable Securities | 0 | 0 |
U.S. Treasury securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 28,711 | 22,878 |
Marketable Securities, Debt, Unrealized Gains | 2 | 102 |
Marketable Securities, Debt, Unrealized Losses | (1,037) | (77) |
Marketable Securities, Debt, Fair Value | 27,676 | 22,903 |
Cash and Cash Equivalents | 2,306 | 3,596 |
Current Marketable Securities | 3,554 | 6,625 |
Non-Current Marketable Securities | 21,816 | 12,682 |
U.S. agency securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 6,561 | 8,949 |
Marketable Securities, Debt, Unrealized Gains | 0 | 2 |
Marketable Securities, Debt, Unrealized Losses | (407) | (64) |
Marketable Securities, Debt, Fair Value | 6,154 | 8,887 |
Cash and Cash Equivalents | 251 | 1,775 |
Current Marketable Securities | 683 | 1,930 |
Non-Current Marketable Securities | 5,220 | 5,182 |
Non-U.S. government securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 18,868 | 20,201 |
Marketable Securities, Debt, Unrealized Gains | 44 | 211 |
Marketable Securities, Debt, Unrealized Losses | (551) | (101) |
Marketable Securities, Debt, Fair Value | 18,361 | 20,311 |
Cash and Cash Equivalents | 25 | 390 |
Current Marketable Securities | 4,526 | 3,091 |
Non-Current Marketable Securities | 13,810 | 16,830 |
Certificates of deposit and time deposits | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 2,872 | 1,300 |
Marketable Securities, Debt, Unrealized Gains | 0 | 0 |
Marketable Securities, Debt, Unrealized Losses | 0 | 0 |
Marketable Securities, Debt, Fair Value | 2,872 | 1,300 |
Cash and Cash Equivalents | 2,221 | 490 |
Current Marketable Securities | 601 | 810 |
Non-Current Marketable Securities | 50 | 0 |
Commercial paper | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 2,913 | 2,639 |
Marketable Securities, Debt, Unrealized Gains | 0 | 0 |
Marketable Securities, Debt, Unrealized Losses | 0 | 0 |
Marketable Securities, Debt, Fair Value | 2,913 | 2,639 |
Cash and Cash Equivalents | 1,310 | 1,776 |
Current Marketable Securities | 1,603 | 863 |
Non-Current Marketable Securities | 0 | 0 |
Corporate debt securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 93,057 | 83,883 |
Marketable Securities, Debt, Unrealized Gains | 94 | 1,242 |
Marketable Securities, Debt, Unrealized Losses | (4,266) | (267) |
Marketable Securities, Debt, Fair Value | 88,885 | 84,858 |
Cash and Cash Equivalents | 34 | 0 |
Current Marketable Securities | 11,309 | 12,327 |
Non-Current Marketable Securities | 77,542 | 72,531 |
Municipal securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 990 | 967 |
Marketable Securities, Debt, Unrealized Gains | 1 | 14 |
Marketable Securities, Debt, Unrealized Losses | (22) | 0 |
Marketable Securities, Debt, Fair Value | 969 | 981 |
Cash and Cash Equivalents | 0 | 0 |
Current Marketable Securities | 162 | 130 |
Non-Current Marketable Securities | 807 | 851 |
Mortgage- and asset-backed securities | Level 2 | ||
Debt Securities, Available-for-sale [Line Items] | ||
Marketable Securities, Debt, Adjusted Cost | 23,613 | 20,529 |
Marketable Securities, Debt, Unrealized Gains | 3 | 171 |
Marketable Securities, Debt, Unrealized Losses | (1,290) | (124) |
Marketable Securities, Debt, Fair Value | 22,326 | 20,576 |
Cash and Cash Equivalents | 0 | 0 |
Current Marketable Securities | 352 | 775 |
Non-Current Marketable Securities | $ 21,974 | $ 19,801 |
Financial Instruments - Non-Cur
Financial Instruments - Non-Current Marketable Debt Securities by Contractual Maturity (Details) $ in Millions | Mar. 26, 2022USD ($) |
Fair value of non-current marketable debt securities by contractual maturity | |
Due after 1 year through 5 years | $ 97,603 |
Due after 5 years through 10 years | 22,899 |
Due after 10 years | 20,717 |
Total fair value | $ 141,219 |
Financial Instruments - Additio
Financial Instruments - Additional Information (Details) - Vendor | 6 Months Ended | 12 Months Ended |
Mar. 26, 2022 | Sep. 25, 2021 | |
Trade receivables | Credit concentration risk | Cellular network carriers | ||
Financial Instruments [Line Items] | ||
Concentration risk, percentage | 36.00% | 42.00% |
Non-trade receivables | Credit concentration risk | ||
Financial Instruments [Line Items] | ||
Number of vendors that individually represented 10% or more of total vendor non-trade receivables | 2 | 3 |
Non-trade receivables | Credit concentration risk | Vendor one | ||
Financial Instruments [Line Items] | ||
Concentration risk, percentage | 52.00% | 52.00% |
Non-trade receivables | Credit concentration risk | Vendor two | ||
Financial Instruments [Line Items] | ||
Concentration risk, percentage | 12.00% | 11.00% |
Non-trade receivables | Credit concentration risk | Vendor three | ||
Financial Instruments [Line Items] | ||
Concentration risk, percentage | 11.00% | |
Hedges of foreign currency exposure associated with revenue and inventory purchases | ||
Financial Instruments [Line Items] | ||
Hedged foreign currency transactions, expected recognition period | 12 months | |
Hedges of foreign currency exposure associated with term debt and marketable securities | ||
Financial Instruments [Line Items] | ||
Hedged foreign currency transactions, expected recognition period | 20 years |
Financial Instruments - Notiona
Financial Instruments - Notional Amounts of Derivative Instruments (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Derivative instruments designated as accounting hedges | Foreign exchange contracts | ||
Derivative [Line Items] | ||
Derivatives, notional amount | $ 65,140 | $ 76,475 |
Derivative instruments designated as accounting hedges | Interest rate contracts | ||
Derivative [Line Items] | ||
Derivatives, notional amount | 20,775 | 16,875 |
Derivatives instruments not designated as accounting hedges | Foreign exchange contracts | ||
Derivative [Line Items] | ||
Derivatives, notional amount | $ 110,758 | $ 126,918 |
Financial Instruments - Derivat
Financial Instruments - Derivative Instruments Designated as Fair Value Hedges and Related Hedged Items (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Current and non-current marketable securities | ||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||
Carrying amount of hedged marketable securities | $ 14,943 | $ 15,954 |
Current and non-current term debt | ||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||
Carrying amount of hedged term debt | $ (19,766) | $ (17,857) |
Condensed Consolidated Financ_3
Condensed Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Gross property, plant and equipment | $ 109,324 | $ 109,723 |
Accumulated depreciation and amortization | (70,020) | (70,283) |
Total property, plant and equipment, net | $ 39,304 | $ 39,440 |
Condensed Consolidated Financ_4
Condensed Consolidated Financial Statement Details - Other Non-Current Liabilities (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Long-term taxes payable | $ 20,711 | $ 24,689 |
Other non-current liabilities | 31,721 | 28,636 |
Total other non-current liabilities | $ 52,432 | $ 53,325 |
Condensed Consolidated Financ_5
Condensed Consolidated Financial Statement Details - Other Income/(Expense), Net (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||
Interest and dividend income | $ 700 | $ 718 | $ 1,350 | $ 1,465 |
Interest expense | (691) | (670) | (1,385) | (1,308) |
Other income/(expense), net | 151 | 460 | (52) | 396 |
Total other income/(expense), net | $ 160 | $ 508 | $ (87) | $ 553 |
Debt - Additional Information (
Debt - Additional Information (Details) - USD ($) $ in Millions | Mar. 26, 2022 | Sep. 25, 2021 |
Debt Instrument [Line Items] | ||
Commercial paper | $ 6,999 | $ 6,000 |
Floating- and fixed-rate notes, aggregate carrying amount | 113,000 | 118,700 |
Commercial paper | ||
Debt Instrument [Line Items] | ||
Commercial paper | 7,000 | 6,000 |
Level 2 | ||
Debt Instrument [Line Items] | ||
Floating- and fixed-rate notes, aggregate fair value | $ 110,500 | $ 125,300 |
Debt - Summary of Cash Flows As
Debt - Summary of Cash Flows Associated with Commercial Paper (Details) - USD ($) $ in Millions | 6 Months Ended | |
Mar. 26, 2022 | Mar. 27, 2021 | |
Maturities 90 days or less: | ||
Proceeds from commercial paper, net | $ 4,952 | $ 2,008 |
Maturities greater than 90 days: | ||
Proceeds from commercial paper | 1,191 | 1,368 |
Repayments of commercial paper | (5,144) | (3,354) |
Repayments of commercial paper, net | (3,953) | (1,986) |
Total proceeds from commercial paper, net | $ 999 | $ 22 |
Shareholders' Equity - Addition
Shareholders' Equity - Additional Information (Details) shares in Millions, $ in Billions | 6 Months Ended |
Mar. 26, 2022USD ($)shares | |
Share Repurchase Program [Line Items] | |
Number of shares repurchased (in shares) | shares | 266 |
Amount of share repurchases | $ | $ 43.3 |
November 2021 accelerated share repurchase agreements | |
Share Repurchase Program [Line Items] | |
Number of shares repurchased (in shares) | shares | 35 |
Amount of share repurchases | $ | $ 6 |
Benefit Plans - Additional Info
Benefit Plans - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total unrecognized compensation cost related to RSUs and stock options | $ 19,300 | $ 19,300 | ||
Total unrecognized compensation cost related to RSUs and stock options, weighted-average recognition period | 2 years 9 months 18 days | |||
Restricted stock units | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Fair value of RSUs as of the respective vesting dates | $ 1,000 | $ 867 | $ 9,500 | $ 9,400 |
Benefit Plans - Restricted Stoc
Benefit Plans - Restricted Stock Units Activity and Related Information (Details) - Restricted stock units $ / shares in Units, shares in Thousands, $ in Millions | 6 Months Ended |
Mar. 26, 2022USD ($)$ / sharesshares | |
Number of Restricted Stock Units | |
Beginning balance (in shares) | shares | 240,427 |
RSUs granted (in shares) | shares | 76,920 |
RSUs vested (in shares) | shares | (62,476) |
RSUs canceled (in shares) | shares | (8,407) |
Ending balance (in shares) | shares | 246,464 |
Weighted-Average Grant Date Fair Value Per RSU | |
Beginning balance (in dollars per share) | $ / shares | $ 75.16 |
RSUs granted (in dollars per share) | $ / shares | 149.72 |
RSUs vested (in dollars per share) | $ / shares | 62.86 |
RSUs canceled (in dollars per share) | $ / shares | 95.86 |
Ending balance (in dollars per share) | $ / shares | $ 100.84 |
Aggregate Fair Value | |
Aggregate fair value of RSUs | $ | $ 43,062 |
Benefit Plans - Summary of Shar
Benefit Plans - Summary of Share-Based Compensation Expense and the Related Income Tax Benefit (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Share-based Payment Arrangement [Abstract] | ||||
Share-based compensation expense | $ 2,252 | $ 1,981 | $ 4,517 | $ 4,001 |
Income tax benefit related to share-based compensation expense | $ (649) | $ (575) | $ (2,185) | $ (2,199) |
Commitments and Contingencies -
Commitments and Contingencies - Changes in Accrued Warranties and Related Costs (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Changes in Accrued Warranties and Related Costs [Roll Forward] | ||||
Beginning accrued warranty and related costs | $ 3,530 | $ 4,124 | $ 3,364 | $ 3,354 |
Cost of warranty claims | (581) | (649) | (1,253) | (1,372) |
Accruals for product warranty | 257 | 309 | 1,095 | 1,802 |
Ending accrued warranty and related costs | $ 3,206 | $ 3,784 | $ 3,206 | $ 3,784 |
Segment Information and Geogr_3
Segment Information and Geographic Data - Information by Reportable Segment (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Segment Reporting Information [Line Items] | ||||
Net sales | $ 97,278 | $ 89,584 | $ 221,223 | $ 201,023 |
Operating income | 29,979 | 27,503 | 71,467 | 61,037 |
Americas | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 40,882 | 34,306 | 92,378 | 80,616 |
Operating income | 15,279 | 12,050 | 34,864 | 27,835 |
Europe | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 23,287 | 22,264 | 53,036 | 49,570 |
Operating income | 8,505 | 8,265 | 20,050 | 17,854 |
Greater China | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 18,343 | 17,728 | 44,126 | 39,041 |
Operating income | 8,112 | 7,758 | 19,295 | 16,288 |
Japan | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 7,724 | 7,742 | 14,831 | 16,027 |
Operating income | 3,496 | 3,428 | 6,845 | 6,931 |
Rest of Asia Pacific | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 7,042 | 7,544 | 16,852 | 15,769 |
Operating income | $ 2,823 | $ 2,736 | $ 6,818 | $ 5,689 |
Segment Information and Geogr_4
Segment Information and Geographic Data - Reconciliation of Segment Operating Income to the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 26, 2022 | Mar. 27, 2021 | Mar. 26, 2022 | Mar. 27, 2021 | |
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Operating income | $ 29,979 | $ 27,503 | $ 71,467 | $ 61,037 |
Research and development expense | (6,387) | (5,262) | (12,693) | (10,425) |
Operating segments | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Operating income | 38,215 | 34,237 | 87,872 | 74,597 |
Segment reconciling items | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Research and development expense | (6,387) | (5,262) | (12,693) | (10,425) |
Corporate non-segment | ||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||
Other corporate expenses, net | $ (1,849) | $ (1,472) | $ (3,712) | $ (3,135) |